Financial Snapshot

Revenue
$574.5M
TTM
Gross Margin
86.82%
TTM
Net Earnings
-$78.58M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
177.03%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$434.8M
Q3 2024
Cash
Q3 2024
P/E
-36.68
Nov 14, 2024 EST
Free Cash Flow
$2.241M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $493.6M $383.5M $277.0M $139.7M $51.13M $6.829M
YoY Change 28.73% 38.45% 98.31% 173.17% 648.7%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $493.6M $383.5M $277.0M $139.7M $51.13M $6.829M
Cost Of Revenue $59.07M $44.51M $24.76M $13.11M $5.911M $1.281M
Gross Profit $434.6M $339.0M $252.2M $126.6M $45.22M $5.548M
Gross Profit Margin 88.03% 88.39% 91.06% 90.62% 88.44% 81.24%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $361.1M $292.8M $190.4M $89.75M $37.20M $10.70M
YoY Change 23.3% 53.83% 112.12% 141.27% 247.7%
% of Gross Profit 83.09% 86.39% 75.47% 70.91% 82.26% 192.83%
Research & Development $87.53M $74.22M $51.02M $18.40M $7.220M $3.990M
YoY Change 17.94% 45.48% 177.29% 154.83% 80.95%
% of Gross Profit 20.14% 21.9% 20.23% 14.54% 15.97% 71.92%
Depreciation & Amortization $6.890M $4.673M $3.034M $1.385M $614.0K $283.0K
YoY Change 47.44% 54.02% 119.06% 125.57% 116.96%
% of Gross Profit 1.59% 1.38% 1.2% 1.09% 1.36% 5.1%
Operating Expenses $448.6M $367.1M $241.4M $108.1M $44.42M $14.69M
YoY Change 22.21% 52.07% 123.2% 143.48% 202.4%
Operating Profit -$14.03M -$28.10M $10.84M $18.42M $801.0K -$9.140M
YoY Change -50.06% -359.12% -41.13% 2199.5% -108.76%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $196.0K $294.0K $295.0K $1.135M $920.0K $887.0K
YoY Change -33.33% -0.34% -74.01% 23.37% 3.72%
% of Operating Profit 2.72% 6.16% 114.86%
Other Income/Expense, Net $18.28M $1.914M -$159.0K -$4.630M -$1.993M -$1.013M
YoY Change 854.96% -1303.77% -96.57% 132.31% 96.74%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income $4.246M -$26.19M $10.69M $13.79M -$1.192M -$10.15M
YoY Change -116.22% -345.06% -22.51% -1256.8% -88.26%
Income Tax $5.882M $3.082M $845.0K $0.00 $0.00 $0.00
% Of Pretax Income 138.53% 7.91% 0.0%
Net Earnings -$1.636M -$29.27M $9.840M $13.79M -$1.192M -$10.15M
YoY Change -94.41% -397.43% -28.64% -1256.8% -88.26%
Net Earnings / Revenue -0.33% -7.63% 3.55% 9.87% -2.33% -148.67%
Basic Earnings Per Share -$0.03 -$0.55 $0.20 $0.43 -$0.20 -$2.01
Diluted Earnings Per Share -$0.03 -$0.55 $0.18 $0.27 -$0.20 -$2.01

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $115.5M $326.4M $176.1M $164.2M $23.60M $21.80M
YoY Change -64.63% 85.35% 7.25% 595.76% 8.26%
Cash & Equivalents $38.60M $60.22M $92.75M $114.2M $23.60M $21.80M
Short-Term Investments $76.86M $266.2M $83.35M $50.00M
Other Short-Term Assets $7.092M $5.312M $5.694M $2.900M $600.0K $900.0K
YoY Change 33.51% -6.71% 96.34% 383.33% -33.33%
Inventory $42.90M $32.58M $21.05M $10.60M $4.000M $1.100M
Prepaid Expenses
Receivables $70.12M $58.61M $42.35M $28.00M $11.30M $2.200M
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $235.6M $422.9M $245.2M $205.7M $39.40M $26.00M
YoY Change -44.3% 72.47% 19.2% 422.08% 51.54%
Property, Plant & Equipment $69.34M $72.36M $61.38M $7.500M $3.300M $900.0K
YoY Change -4.18% 17.89% 718.4% 127.27% 266.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.500M $8.300M $3.983M
YoY Change -81.93% 108.39%
Other Assets $2.617M $589.0K $981.0K $900.0K $1.800M $0.00
YoY Change 344.31% -39.96% 9.0% -50.0%
Total Long-Term Assets $438.7M $81.25M $66.34M $8.400M $5.100M $900.0K
YoY Change 439.92% 22.46% 689.81% 64.71% 466.67%
Total Assets $674.2M $504.2M $311.5M $214.1M $44.50M $26.90M
YoY Change
Accounts Payable $10.58M $7.659M $6.541M $3.000M $2.500M $700.0K
YoY Change 38.1% 17.09% 118.03% 20.0% 257.14%
Accrued Expenses $65.76M $48.52M $35.97M $10.80M $6.300M $1.400M
YoY Change 35.55% 34.87% 233.07% 71.43% 350.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $76.34M $56.17M $42.51M $13.80M $8.900M $2.100M
YoY Change 35.9% 32.13% 208.07% 55.06% 323.81%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $19.50M $9.800M
YoY Change -100.0% 98.98%
Other Long-Term Liabilities $96.76M $30.98M $29.82M $0.00 $1.200M $200.0K
YoY Change 212.35% 3.88% -100.0% 500.0%
Total Long-Term Liabilities $96.76M $30.98M $29.82M $0.00 $20.70M $10.00M
YoY Change 212.35% 3.88% -100.0% 107.0%
Total Liabilities $209.3M $87.15M $72.33M $13.80M $29.50M $12.20M
YoY Change 140.19% 20.48% 424.15% -53.22% 141.8%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 56.77M shares 52.84M 49.82M 32.03M 5.888M 5.057M
Diluted Shares Outstanding 56.77M shares 52.84M 55.59M 51.55M 5.888M 5.057M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.8827 Billion

About Inari Medical Inc

Inari Medical, Inc. operates as a medical device company. The company is headquartered in Irvine, California and currently employs 1,300 full-time employees. The company went IPO on 2020-05-22. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. The company also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES Axonics, Inc. QuidelOrtho Corp Envista Holdings Corp Inspire Medical Systems Inc Integra Lifesciences Holdings Corp iRhythm Technologies Inc Omnicell Inc Tandem Diabetes Care Inc